Role of Allogeneic Transplantation in Multiple Myeloma in the Era of New Drugs by Bruno, Benedetto et al.
Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Perspectives
Role  of  Allogeneic  Transplantation  in  Multiple 
Drugs
Benedetto Bruno, Luisa Giaccone, Moreno Festuccia and Mario Boccadoro.
Division of Hematology at the S. Giovanni Battista Hospital, University of Torino, Via Genova 3, Torino, 
Italy.
Correspondence to: Benedetto Bruno, M.D., Ph.D., Divisione Universitaria di Ematologia, Azienda Ospedaliera San 
Giovanni Battista, Via Genova 3, 10126, TORINO, Italy, Phone +39
Competing interests: The author have declared th
Published: June 1,  2010
Received:  May 10, 2010
Accepted: May 31, 2010
Medit J Hemat Infect Dis 2010, 2(2): e2010013, 
This article is available from: http://www.mjhid.org/article/view/5944
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited.
   
Abstract
High-dose melphalan with autologous stem cell rescue has been regarded as the standard of 
care for patients with newly diagnosed myeloma up to the age of 65
development of agents with potent anti
bortezomib has further improved overall survival and response rates. However, relapse is a 
continuous risk.
Allografting is a potentially curative treatment for a subset of multiple myeloma patients for 
its well documented graft-vs-myeloma
though molecular remissions have been reported up to 50% after high
conditionings, their applications, given the high toxicity, have been for long limited to younger 
relapsed/refractory  patients.  These  limitations  have  greatly  been  reduced  through  the 
introduction of non-myeloablative/reduced
The introduction of new drugs, characterised by low risks of early mortality, indeed requires 
to define  role  and timing  of an all
benefit from graft-vs-myeloma effects.   
Ultimately, new drugs should not be viewed as mutually exclusive with an allograft. They may 
be  employed  to  achieve  profound  cytoreduction  before  and  enhance 
effects as consolidation/maintenance  therapy after an allograft. However, this combination 
should be explored only in well-designed clinical trials. 
Introduction: Multiple myeloma is a fatal plasma 
cell  disorder,  though  recent  advances  in  the 
understanding  of  its  pathogenesis  has  identified 
peculiar  mechanisms  that  have  become  targets of 
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melphalan with autologous stem cell rescue has been regarded as the standard of 
care for patients with newly diagnosed myeloma up to the age of 65-70 years. The recent 
development of agents with potent anti-tumor activity such as thalidomide, lenalidomide 
bortezomib has further improved overall survival and response rates. However, relapse is a 
Allografting is a potentially curative treatment for a subset of multiple myeloma patients for 
myeloma effects. However, its role has been hotly debated. Even 
though molecular remissions have been reported up to 50% after high-dose myeloablative 
conditionings, their applications, given the high toxicity, have been for long limited to younger 
s.  These  limitations  have  greatly  been  reduced  through  the 
myeloablative/reduced-intensity conditionings. 
The introduction of new drugs, characterised by low risks of early mortality, indeed requires 
to define  role  and timing of  an allograft to capture the subset  of patients who  may most 
effects.   
Ultimately, new drugs should not be viewed as mutually exclusive with an allograft. They may 
be  employed  to  achieve  profound  cytoreduction  before  and  enhance  graft-
effects as consolidation/maintenance therapy after an allograft. However, this combination 
designed clinical trials. 
Multiple myeloma is a fatal plasma 
cell  disorder,  though  recent  advances  in  the 
understanding  of  its  pathogenesis  has  identified 
peculiar  mechanisms  that  have  become  targets  of 
agents  with  potent  anti-myeloma  activity  such  as 
lenalidomide  and bortezomib.  High
chemotherapy  and  autologous  transplantation 
with/without these newer agents has been regarded 
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melphalan with autologous stem cell rescue has been regarded as the standard of 
70 years. The recent 
tumor activity such as thalidomide, lenalidomide and 
bortezomib has further improved overall survival and response rates. However, relapse is a 
Allografting is a potentially curative treatment for a subset of multiple myeloma patients for 
ever, its role has been hotly debated. Even 
dose myeloablative 
conditionings, their applications, given the high toxicity, have been for long limited to younger 
s.  These  limitations  have  greatly  been  reduced  through  the 
The introduction of new drugs, characterised by low risks of early mortality, indeed requires 
ograft to capture  the subset of  patients who may most 
Ultimately, new drugs should not be viewed as mutually exclusive with an allograft. They may 
-versus-myeloma 
effects as consolidation/maintenance therapy after an allograft. However, this combination 
myeloma  activity  such  as 
bortezomib.  High-dose 
chemotherapy  and  autologous  transplantation 
with/without these newer agents has been regarded Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
as standard treatment for newly diagnosed younger 
patients. Disease  recurrence  is,  however,  a 
continuous  risk. Allografting  appears  the  only 
potentially  curative  treatment on  account  of well-
documented graft-vs-myeloma effects. 
Between  1989  and  2008,  1089  allogeneic 
transplants  were  performed  in  Italy  through  the 
activity of the Gruppo Italiano Trapianto di Midollo 
(GITMO) (Figure 1). This clinical activity may be 
divided into three main periods. Up to the late 90’, 
intense  myeloablative  conditionings  were 
employed. Given their high mortality and toxicity, 
their  application  was  primarily  limited  to  heavily 
pretreated  patients  at  relapse  or  refractory  to 
chemotherapies. 
The introduction of reduced-intensity and non-
myeloablative  conditionings  greatly  renewed  the 
interest  in  allografting  and  the  incidence  of  this 
procedure  peaked  in  the  early  2000’.  These 
regimens allowed to increase the eligible age for an 
allograft  up  to  70  years  even  in  medically  unfit 
patients.  Moreover,  the  burden  of  myeloma 
eradication was shifted from chemotherapy to donor 
T cells. 
More  recently,  with  the  introduction  of  new 
drugs, the number of transplants has declined even 
though  the  use  of  unrelated  donors  appears 
increased.
This manuscript aims at reviewing the current 
evidence  of  graft-vs-myeloma effects;  the  results 
obtained  with  conventional  myeloablative  and, 
more  recently,  with  non-myeloablative 
conditionings;  and  the  possible  integration  of  so-
called  new  drugs  in  the  setting  of  allografting to 
improve clinical outcomes. 
Myeloablative conditioning regimens (Table 1): 
The  most  commonly  used  myeloablative 
conditioning regimens included cyclophosphamide 
with  total body  irradiation  or  busulfan,  or 
melphalan and total body irradiation.
1-13
Figure 1. Number of transplants / year performed in Italy since 1989 through the Gruppo Italiano Trapianto di Midollo. The gray 
area represents transplants from unrelated donors (MUD). The clinical activity may be divided into three main periods: intense 
myeloablative  conditionings  were  employed  up  to  the  late  90’;  reduced-intensity  and  non-myeloablative  conditionings  greatly 
renewed the interest in allografting in the early 2000’. More recently, with the introduction of new drugs, the number of transplants 
has declined. However, the use of unrelated donors appears increased.Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Table 1. Myeloablative Conditioning Regimens for Allografting in Multiple Myeloma 
Author Patients
Median Age
(years)
Conditioning
Transplant-
Related Mortality
%
Complete 
Remission
%
Overall 
Survival
%
Bensinger 
et al.
136
43-48
(<60)
Bu, Cy, +Total Body Irradiation
48 (at day 100)
63 (at 1 year)
34 22  (at 5 years)
Barlogie 
et al.
36 <55
Melphalan (100 mg/m
2), Total Body 
Irradiation (12Gy)
53 (at 1 year) --- 39  (at 7 years)
Reece 
et al.
26 43
Cy, Total Body Irradiation
Bu,Cy
Melphalan (100 mg/m
2), Total Body 
Irradiation
19 (at day 100) 62 47  (at 3 years)
Alyea 
et al.
24 46
Cy, Total Body Irradiation (14Gy)
Bu,Cy
10 --- 55  (at 2 years)
Kulkarni 
et al.
33 38
Melphalan (110 mg/m
2), Total Body 
Irradiation (10.5Gy) Cy, Total Body 
Irradiation (9.5Gy)
Cy, Melphalan
Bu,Cy
54 37 36 (at 3 years)
Le Blanc 
et al.
37 47
Cy, TBI (12Gy)
Melphalan (140 mg/m
2), Total Body 
Irradiation (10.5Gy)
Bu,Cy
Others
22 57
32 (at 40 
months)
Couban 
et al.
22 43
Melphalan (160 mg/m
2), Total Body 
Irradiation (12Gy)
Cy, TBI (12Gy)
Bu,Cy
59 50 32 (at 3 years)
Varterasian 
et al.
24 43
Cy, Total Body Irradiation
Melphalan, Total Body Irradiation
Bu,Cy, Total Marrow Irradiation
Others
25 --- 40 (at 3 years)
Abbreviations: Bu: Busulfan; Cy: cyclophosphamide)
The  high  transplant-related  mortality  up  to  60% 
limited  this  approach  to  young,  medically  fit 
patients.
1-3 Causes  of  death  comprised  regimen-
related,  graft-vs-host  disease  (GvHD)  and  its 
transplant-related  complications.  Strong  myeloma 
effects  on  baseline  organ  functions  and  severe 
immunodeficiency  may  be  responsible  for 
transplant-related  mortality  observed  in  other 
malignancies.  Most  representative  experiences  on 
the use of myeloablative conditioning regimens in 
multiple  myeloma  come  from  Seattle,  the  US 
Intergroup  Trial  S9321,  and  a  European  Bone 
Marrow  Transplantation  (EBMT)  Registry 
study.
2,4,14 The  largest  single-center  experience 
comes  from  the  Seattle  group  at  the  Fred 
Hutchinson  Cancer  Research  Center.
2,5 One-
hundred-thirty-six  heavily  pre-treated  or  disease 
refractory  patients  received  an  allograft  between 
1987  and  1999  from  related  (84%)  or  unrelated 
donors  (16%).  A  day-100  transplant-related 
mortality of 48% was reported. The 5-year survival 
was 22% with disease-free survival of 14%. In 34% 
of  patients  who  achieved  complete  remission, 
overall and disease-free survivals  at 5 years were 
48% and 37%. Subgroup analyses showed that early 
transplant-related mortality was approximately 20% 
for patients with chemo-sensitive disease who were 
transplanted within one year from diagnosis.  
A  North-American  prospective trial  compared 
autografting  with  myeloablative  allografting.
4 The 
US  intergroup  trial  (S9321)  of  early  vs  late 
autografting  included  a  third  option  that  alloweMedit J Hemat Infect Dis 2010; 2(2); Open Journal System 
patients with HLA-identical siblings, under the age 
of 55, to undergo an allograft after melphalan and 
total  body  irradiation.  This  arm of  the study  was 
prematurly  closed  after  the  first  36  patients  were 
enrolled  given  an  excessively  high  transplant-
related mortality of  53%. After  a  follow  up  of  7 
years, however, the overall survivals were identical 
at  39%  for  both  autologous  and  allogeneic 
recipients, while the progression-free survivals were 
15% for autologous recipients as compared to 22% 
for  allogeneic  recipients,  respectively.  However, 
while the risk of relapse and death continues in the 
cohorts  treated  with  an  autograft,  the  overall 
survival curve for the allogeneic cohort reached a 
plateau with follow up extending to 10  years.
A  large  retrospective  registry  analysis  by  the 
EBMT group showed a remarkable improvement in 
overall survival in the late 90’ due to a reduction in 
transplant-related  mortality  through  improved 
supportive care and more careful patient selection.
14
In  this  analysis,  690  patients,  median  age  at 
transplant 44 years, who underwent a myeloablative 
allograft  were  divided  into  two  cohorts:  patients 
who  received  a  bone  marrow  allograft  between 
1983-93 and those between 1994-98. In this latter 
cohort,  some  patients  also  received  granulocyte-
colony-stimulating  factor  (G-CSF)  mobilized 
peripheral  blood  hematopoietic  cells.  Transplant-
related mortality at 6 and 24 months was lower in 
the  cohort  transplanted  between  1994-1998  than 
between  1983-1993,  21%  versus  38%  and  30% 
versus  46%.  The  reduced  toxicity  was  associated 
with  an  increase  in  overall  and  progression-free 
survivals at 3 years from 35% to 55% and from 7 to 
19 months for patients transplanted between 1994-
1998.  Furthermore,  no  differences  in  clinical 
outcomes  were  observed  between  patients  who 
received marrow and those who received peripheral 
blood hematopoietic cells. 
The  interpretation  of  these  studies  to  draw 
definitive conclusions is extremely difficult as the 
reported patients were not included in prospective 
control trials. Most patients were heavily pretreated, 
were chemo-resistant at the time of transplant and 
received  a  variety  of  conditionings and  GvHD 
prophylaxes. The most consistent finding, however, 
was the high treatment-related mortality. 
Despite selection bias, it was widely assumed 
that better clinical outcomes were associated with 
patients  with  chemo-sensitive  myeloma  at 
transplant. In most studies, only 10-25% of patients 
eventually became long-term disease-free survivors 
and were possibly cured.
Reduced-intensity  and  non-myeloablative 
conditioning regimens (Table 2): Though higher 
in  multiple  myeloma,  the  transplant-related 
morbidity  and  mortality  associated  with 
myeloablative  conditioning  regimens  and 
allografting  for  the  treatment  of  hematological 
malignancies have always been a matter of concern. 
These clinical observations prompted investigators, 
in  the  late  90’,  to  explore  highly 
immunosuppressive, though less myelosuppressive 
and less intense, conditionings which could possibly 
establish  stable donor  engraftment  while reducing 
transplant-related  organ  toxicities.  Pioneering 
studies  were  carried  out  in  Seattle  where  it  was 
shown  that  donor  engraftment  could  be  obtained 
with  the  sole  combination  of  low  dose  non-
myeloablative total body irradiation (200 cGy) and 
fludarabine, followed by peripheral blood stem cells 
and  potent  immunosuppression  with  cyclosporine 
and mycophenolate mofetil.
15 Shortly thereafter, the 
tandem  approach  of  an  autologous  transplant 
followed, 2-4 months later, by a non-myeloablative 
allograft was also designed for patients with newly 
diagnosed  multiple  myeloma.
16 In  52  patients 
treated  with  this  tandem  modality  the  complete 
remission  rate  was  48%  while  progression  free 
survival  and  overall  survival  were  48%  and  69% 
respectively. The same “tandem concept” was also 
developed  by  Kroger  et  al  using  melphalan, 
fludarabine  and  anti-thymocyte  globulin  with 
related and unrelated donors.
17
The  tandem  approach  of  an  autologous 
transplant  followed  by  a  low  dose  non-
myeloablative total body irradiation has become the 
most  widely  used  conditioning  for  myeloma 
patients. The rationale for this tandem “autologous-
allogeneic”  approach  was  to  separate  in  time  the 
high-dose cytoreduction with melphalan at standard 
200  mg/m
2 and  the  graft-vs-myeloma  effect  with
the  potential  of  drastically  reducing  treatment-
related toxicity and mortality. 
Two  large  series  from  Seattle  and  Italy  have 
recently reported on more than 200 patients using 
the  tandem  auto/allo  strategy.  Long-term  clinical 
outcomes of 102 patents treated with this approach, 
after  a  follow  up  of  6.3  years,  were  recently 
reported by Rotta et al.
18 However, unlike the first 
report  by  the  same  group,  patients  were  not 
uniformly  in first  line treatment. Overall,  42%  of 
patients  developed  grade  II-IV  acute  GvHD  and 
74% experienced chronic GvHD. Transplant-related 
mortality at 5 years was 18%, mostly due to GvHD 
and/or infections. Overall response rate was 94%, 
with 65% and 29% of patients achieving complete Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Table 2. Non-myeloablative/Reduced Intensity Conditioning Regimens for Allografting in Multiple Myeloma 
Abbreviations: Bu: Busulfan; Fluda: fludarabine; ATG anti-thymocyte globulin
and partial remissions respectively. Median overall 
survival  was  not  reached  and  progression-free 
survival was 3 years. Estimated 5 year overall and 
progression  free  survivals  were  64%  and  36%. 
Results were recently reported also by the Gruppo 
Italiano Trapianti di Midollo.
19 One-hundred newly 
diagnosed  patients  younger  than  65  years  were 
registered  in  a  prospective  multi-center  study. 
Major strength of the study was the rigid enrolment 
of untreated myeloma patients who underwent the 
same  vincristin,  adriamycin  and  dexamethasone 
(VAD)-based  induction  before  the  autologous 
cytoreductive  transplant.  Primary  objectives  were 
overall  and  event-free  survivals  from  diagnosis. 
After  a  median  follow  up  of  5  years,  overall 
survival  was  not  reached  and  event  free  survival 
was  37  months.  Incidences  of  acute  and  chronic 
GvHD were 38% and 50%, respectively. Complete 
remission,  achieved  in  53%  of  patients,  or  very 
good  partial  remission  prior  to  allografting  were 
significantly associated with achievement of  post-
transplant remission and longer event-free survival. 
Interestingly, in both studies from Seattle and from 
the  Italy  graft-vs-myeloma  effects  were  not 
associated with clinical GvHD.
In  recent  years,  several  reduce-intensity 
regimens have been designed including melphalan, 
100-140  mg/m
2,  with  or  without  fludarabine,  and 
intermediate-dose  busulfan.
20-27 Moreover,  anti-
thymocyte  globulin  or  alemtuzumab  have  been 
employed in some trials to reduce GvHD.
20,21 In a 
review  of  the  EBMT  registry,  26  different 
conditioning  regimens,  with/without  T  cell 
depletion, in 229 patients were reported.
28,29 Almost 
80%  of  patients  received  peripheral  blood  stem 
cells. Acute grade II-IV GVHD developed in 31% 
extensive  chronic  GVHD  in  25%.  Transplant-
related mortality was rather low at 22%, however, 3 
year overall survival and progression free survival 
were disappointing at 41% and 21%. Best clinical 
outcome was observed in those patients who were 
transplanted in first remission and did not receive 
more than one autograft. The use of alemtuzumab to 
prevent GVHD had a negative impact on transplant-
related  mortality,  progression  free  survival  and 
overall  survival.  Achievement  of  complete 
remission  and  occurrence  of  chronic  GvHD  were 
Author Patients Conditioning
Transplant-Related 
Mortality
%
Chronic GVHD
%
Complete 
Remission
%
Overall 
Survival
%
Mohty 
et al.
41 Bu, Fluda, ATG 17 41 24 62  (at 2 years)
Peggs 
et al.
20
Total Body Irradiation, Fluda,  
alemtuzumab
15 --- 10 71  (at 2 years)
Einsele 
et al.
22
Total Body Irradiation (2Gy), 
Fluda, Cy
23 32 27 26  (at 2 years)
Giralt 
et al.
22 Fluda , Melphalan (90/140 mg/m
2) 41 27 32 30  (at 2 years)
Gerull 
et al.
52
Total Body Irradiation (2Gy), 
Fluda
17 70 27
41 (at 1.5 
years)
Maloney 
et al.
54
Total Body Irradiation (2Gy)/
Total Body Irradiation (2Gy), 
Fluda
22 60 57 69 (at 5 years)
Lee 
et al.
45
Melphalan (100 mg/m
2), 
Total Body Irradiation (2Gy), 
Fluda
38 13 64 36 (at 3 years)
Kroger 
et al.
17
Melphalan (100 mg/m
2), Fluda, 
ATG
18 7 73 74 (at 2 years)
Kroger 
et al.
21
Melphalan (100-140 mg/m
2), 
Fluda, ATG
24 12 40 74 (at 2 years)Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
associated with prolonged progression free survival. 
It is imperative  to underline  that fact the patients 
cohorts  were  highly  heterogeneous  and  study 
designs greatly differ. No definite conclusions could 
be drawn.  
More  recently,  studies  comparing  allografting 
after  reduced-intensity  conditionings  and 
autografting have been published. The concept of 
Mendelian  or  genetic  randomization  has  been 
applied to the assessment of  outcomes in patients 
with hematological disorders who were treated with 
allografting  or  other  therapies.
30-33  This  concept 
relies  on  the  biological  process  through  which 
offspring randomly inherit genetic traits half from 
each parent so that one in four siblings is expected 
to  have  a  potential  HLA-identical  sibling  donor. 
The comparison  by the intention-to-treat  principle 
between patients with HLA-identical siblings, who 
can be assigned to allografting, and those without 
such siblings, and who cannot receive an allograft, 
is  used  as  a  surrogate  for  an  unbiased 
randomization. 
The first such study was reported by the French 
group.  The  study  compared  two  trials  which 
included  high  risk  myeloma  patients  carrying 
elevated serum β2-microglobulin and del(13).
34 All 
patients underwent an autograft after melphalan at 
200 mg/m
2. Sixty-five patients with HLA-identical 
sibling  donors  then  received  an  allograft  after  a 
conditioning with  busulfan,  fludarabine  and  high-
dose  anti-thymocyte  globulin,  12.5  mg/kg. 
Outcomes  were  compared  with  219  high  risk 
patients who were treated with a second autograft 
after  melphalan  at  220  mg/m
2.  Transplant-related 
mortality  and  response  rates  were  not  different. 
After  a median  follow-up of  2 years,  overall and 
event free survivals were 35% and 25%, and 41% 
and  30%  for  the  double  autologous  and  the 
autologous-allogeneic  cohorts,  respectively.  The 
Authors  concluded  that  patients  with  high  risk 
features  may  not  benefit from a reduced-intensity 
allograft. This study was criticized for the inclusion 
of high dose anti thymocyte globulin, 12.5 mg/kg, 
in  the  conditioning  regimen.  As  a  matter  of  fact, 
though the incidence of chronic GvHD was 7%, the 
high  dose  of  anti-thymocyte  globulin  may  have 
highly  prevented  potentially  curative  graft-vs-
myeloma effects. This study was also updated.
35 By 
intent-to-treat analysis on  all 284 patients, after a 
median follow-up of 56 months, event-free survival 
did  not  significantly  differ  between  tandem 
autologous  and  a  single  autograft  followed  by  a 
reduced–intensity  allograft  (median  22  versus  19 
months,  p 0.58). There was a trend for a superior 
overall  survival  in  the  tandem  autologous  cohort 
(median 48 versus 34 months, p 0.07).  
Another study by Bruno et al. reported on 245 
consecutive newly diagnosed myeloma patients, up 
to  the age of  65  years,  diagnosed  between  1998-
2004 where 162 out of 199 with at least one sibling 
were  HLA-typed  with  their  potential  sibling 
donors.
36The novelty of the study was the treatment 
assignment in function of the presence/absence of 
an  HLA-identical  sibling  donor.  Patients  received 
induction with VAD-based regimens followed by a 
standard autograft with melphalan. Eighty patients 
with at least one HLA-identical sibling were offered 
total  body  irradiation  -based  non-myeloablative 
conditioning followed by an allograft with G-CSF 
mobilized peripheral blood stem cells. Eighty-two 
patients  without  an  HLA-identical  sibling  were 
assigned  to receive  a second autograft after high-
dose,  140-200  mg/m
2,  or  intermediate-dose,  100 
mg/m
2, of melphalan. After a median follow up of 
45  months,  overall  and  event-free  survivals  were 
significantly  longer  in  patients  with  donors:  80 
versus  54  months  and  35  versus  29  months.  By 
multivariate  analysis,  having  an  HLA-identical 
sibling  was  an  independent  variable  significantly 
associated  with  longer  overall  and  event-free 
survivals. Overall, 58 and 46 patients completed the 
tandem  autologous-allogeneic  and  the  tandem 
autologous programs, with complete remission rates 
of  55%  versus  26%.  Transplant-related  mortality 
was  10%  and  2%  respectively.  Median  overall 
survival was not reached in the tandem autologous-
allogeneic cohort and was 58 months in the tandem 
autologous cohort. Event-free survival was 43 and 
33  months,  respectively.  Criticisms  to  the  study 
were that only 58 and 46 patients in in the tandem 
autologous-allogeneic  cohort  and  in  the  tandem 
autologous  cohort,  respectively,  completed  their 
assigned treatments and the relatively poor outcome 
of  the  patients  assigned  to  the  tandem  autograft. 
This study was also updated after a median follow 
up of 6 years. Overall survival was not reached for 
the 80 patients with an HLA-identical sibling and 
was 52 months for  those without, p=0.004; event 
free  survival  remained  significantly  longer  in 
patients with HLA-identical siblings: 35 versus 29 
months, p=0.009. Median overall survival was not 
reached  in  the  58  patients  who  completed  the 
tandem autologous-allogeneic program and was 64 
months  in  the  46  who  completed  the  double 
autologous  program,  p=0.04.  Event-free  survival 
was 37 and 33 months p=0.06.
A  third  biologically  randomized  study  was 
reported by the Spanish PETHEMA group.
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hundred-ten patients, after failing to reach at least 
near-complete  remission  after  a  first  autograft, 
received  either a second autograft (No. 85) or an 
allograft  (No.25)  after  a  reduced-intensity 
conditioning with melphalan and fludarabine. There 
was a higher complete remission rate, 40% versus 
11%,  p=0.001,  and  a  trend  towards  a  longer 
progression-free survival, median 31 months versus 
not reached, p=0.08, in the reduced-intensity group. 
Patients who underwent an allograft showed a trend 
towards a higher transplant-related mortality, 16% 
versus 5%, p=0.07, and no difference in overall and 
event-free survivals. 
Finally, 4 large prospective randomized studies, 
the  Blood  and  Marrow  Transplant  Clinical  Trials 
Network (BMT-CTN) 0102 trial in the U.S.A.; the 
Dutch-Belgian  Hemato-Oncology  Cooperative 
Group (HOVON) trial,
38 the EBMT trial
39 and the 
study  by  the  German  DSMM  group
40 in  Europe, 
have recently been presented. 
The  large  BMT-CTN 0102  trial  comparing 
double  autologous  transplant  versus  tandem 
autologous/non-myeloablative allogeneic transplant 
completed the  accrual  in March  2007.  More than 
150  patients  were  biologically  randomized  to  the 
latter cohort. The results from this study are eagerly 
awaited and should be released in 2010.
In  the  HOVON  54  study,  newly  diagnosed 
patients  with  an  HLA-identical  sibling  donor 
included in the HOVON 50 study, a phase 3 study 
for  the  evaluation  of  thalidomide  combined  with 
high-dose melphalan, were allowed to proceed to a 
non-myeloablative allogeneic transplant from 2 and 
6  months  after  a  standard  autograft,  whereas 
patients without a suitable donor were randomized 
to thalidomide or interferon maintenance. By intent-
to-treat analysis, no difference in progression free 
survival and overall survival were observed with an 
interim analysis that  included 126 patients with a 
donor and 141 patients without.
38
In the EBMT trial, progression free survival at 
60 months was 35% for the tandem auto/allo cohort 
as compared to 18% for double auto, and overall 
survival  65%  and  57%  respectively.
39 This  trend 
was observed in both deletion 13 and non-deletion 
13 patients. Final analyses of the Hovon and of the 
EBMT trials are expected in 2010.
Another  prospective  study comparing  double 
autologous  transplant  versus  tandem 
autologous/reduced-intensity  allogeneic  transplant, 
after  a  conditioning  with  fludarabine  and 
melphalan,  has  been  reported  by  the  German 
DSMM.
40 This  study  only  included  patients  with 
deletion  13q14.  Transplants  from  HLA-matched 
unrelated  donors  were  allowed.  Preliminary  data 
showed a higher complete remission rate in patients 
with  deletion 13q14 who  received  an  allograft  as 
compared to the autologous group (59% versus 32 
%.p.  0.003).  However,  the  projected  overall 
survival  at  3  years  was  70%  for  the  double 
autologous group and 60% for the allogeneic group 
(P=0.22). In the latter, transplant-related mortality 
at  2  years  was  only  12.7%  even  though  60%  of 
patients  received  an  allograft  from  an  unrelated 
donor.  
The  potentially  curative  role  of allografting: 
graft-vs-myeloma: The potentially unique, curative 
role of allografting consist of the immune reaction 
of donor T cells against myeloma cells through the 
recognition  of  possibly  disease-specific  antigens.
Evidence  for  the  existence  of  such  reactions  was 
initially  documented  by  the  achievement  of 
complete  remissions  after  the  discontinuation  of 
immunosuppression or after the infusion of donor T 
lymphocytes in patients with recurrent disease post-
transplant.
41-43 Some  Authors,  however,  reported 
that the strongest predictors for response to donor 
lymphocyte  infusions  were  acute  and  chronic 
GvHD
44-47 indicating  that  GvHD  and  graft-vs.-
myeloma  may  share  the  same  antigenic  targets. 
Chronic  GVHD has   been  associated with  longer 
response  duration  and  prolonged  overall  survival. 
Recently, the Gruppo Italiano Trapianti di Midollo 
(GITMO), however, reported that the development 
of  chronic  GVHD  did  not  correlate  with  the 
remission  rates  and  response  duration.
19 Thus, 
subclinical graft-vs.-host reactions, especially after 
a non-mieloablative conditioning, may occur in the 
absence  of  detrimental  GVHD.  Finally,  further 
evidence  for  graft-vs-myeloma  are  the  molecular 
remissions,  prelude  to  possible  complete 
eradication, that have been reported up to 50% of 
patients following allografting.
48
Role of “new drugs”: So called “new drugs” have 
greatly changed the treatment options for multiple 
myeloma. Not only do they target malignant plasma 
cells but also affect their cross-talk with the marrow 
microenvironment  due  to  several 
immunomodulatory  properties.  Interestingly,  they 
modulate  T  cell  subpopulations  that  may  play  a 
pivotal role in graft-vs-myeloma effects. Thus, their 
role  in  combination  with  allografting  should  be 
extensively investigated.    
Thalidomide,  lenalidomide  and  bortezomib 
have  recently  been  included  in  a  number  of 
randomized clinical trials in both young and elderly Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
patients.
49-52 Response rates have significantly been 
improved even though longer follow-up is needed 
to  evaluate  the  impact  on  long-term  overall 
survival.     
In the setting of allografting, these new drugs 
have first been employed in patients relapsing after 
allografting. The addition of thalidomide to donor 
lymphocyte infusions improved efficacy of salvage 
treatment without increasing  GvHD.
53
Remarkable  results  have  been  obtained  with 
lenalidomide  in  a  cohort  of  patients  with 
progressive  disease  after  reduced-intensity 
allografting.
54-55 In  a  study,  14/15  (93%)  patients 
responded;  however,  a  severe  flare  of  GVHD  in 
some patients was observed. Lenalidomide has also 
been  employed  as  maintenance  treatment  to 
enhance graft-vs-myeloa in a prospective phase II 
study  by  the  HOVON  group.
56 After,  an 
autologous/non-myeloablative  tandem  transplant, 
patients were given lenalidomide at the dose of 10 
mg/day  for  21  days  and  then  7  days  of  rest. 
Treatment  was  started  between  1  and  6  months 
post-transplant  in  patients  with  no  GvHD. 
Preliminary results showed a drop out rate of 41% 
primarily due to acute flare of severe GVHD that 
strongly  correlated  with  the  start  of  maintenance. 
Given  this  recently  reported  toxicity  profile,  the 
GITMO  group  is  conducting  a  study  where 
lenalidomide, employed as maintenance, is started 
at  6  months  post  non-myeloablative  transplant  in 
patients without signs and/or symptoms of chronic 
GVHD.
Bortezomib has also been shown to be effective 
in patients with relapsed disease.
57-60 Interestingly, 
bortezomib  may  play  a  role  in  the 
immunomodulation  of  GVHD:  in  a  preclinical 
murine  model,  it  down-regulated  cytokine 
synthesis,  induced  T  cell  apoptosis,  prevented 
GvHD. Importantly, graft-vs-tumor effects were not 
affected.
61,62 More  recently,  Blanco  et  al  showed 
that bortezomib induced selective depletion of allo-
reactive T lymphocytes, decreased the production of 
Th1  cytokines  and  allowed  the  emergence  of  a 
suppressor T cell subset.
63,64 Of note, another study 
has shown that the combination of bortezomib with 
tacrolimus and methotrexate was very effective in 
the  prevention  of  GvHD  after  reduced-intensity 
allografts  from  HLA-mismatched  unrelated 
donors.
65 These  findings  appear  attractive  for 
studies in myeloma patients.  
Conclusions:  Overall,  myeloablative  allografts 
have  cured  a  minority  of  patients  who  obtained 
complete  clinical  remission  after  transplant. 
Reduced-intensity  and  non-myeloablative 
conditionings  represent  a  clinical  and  biological 
breakthrough  given  that  toxicity  was  greatly 
reduced  and  the  existence  of  graft-vs-myeloma 
effects were indubitably shown. Long-term disease 
control and disabling chronic GVHD in a subset of 
patients represent important issues. 
If  an  allograft  should  be  part  of  first-line 
treatment  plans  or  of salvage  therapy  for 
refractory/relapsed patients is still hotly debated. In 
newly  diagnosed  patients  with  chemosensitive 
disease,  therefore  in  complete  or  very  good 
remissions,  a  non-myeloablative  conditioning 
would  safely  allow  for  donor  engraftment  with a 
reduced risk of toxicity and would potentially add a 
curative    graft.vs.myeloma  effect  in  a  subset  of 
patients. To  support  this, many reports show that 
better  outcome  is  associated  with  chemosensitive 
disease  at  transplant  and  that  allografting  at  an 
earlier  disease  phase  is  associated  with  stronger 
graft-vs-myeloma  effects.
66,67 This  almost 
unanimously reported observation may be related to 
an antigen expression profile of potential targets for 
donor  T  cells  that  change  through  the  disease 
phases. Siegel et al. reported the identification of 
HLA-A*0201-presented  T  cell  epitopes,  derived 
from  the  oncofetal  antigen-immature  laminin 
receptor  protein,  in  many  haematological 
malignancies.
68 However,  it  was  interestingly 
observed that the  expression of  these antigens on 
plasma cells was lost over time. Even though very 
different in design, long-term results of donor-vs-
no  donor  comparisons  of  the  Blood  and  Marrow 
Transplant  Clinical  Trials  Network  (BMT  CTN), 
the  Dutch  Hovon,  the  EBMT,  and  the  German 
DSMM studies may allow valuable information on 
the use of up-front allografting. 
Other  Authors  underline  the  fact  that  new 
treatment schemas may likely translate into longer 
overall survival and would be more inclined to offer 
an allograft at relapse. In this case, however, disease 
reduction  prior  to  transplant  and  a  more  intense 
conditioning,  rather  than  a  non-myeloablative 
regimen, would be required despite a higher risk of 
toxicity.  
In conclusion, future studies cannot be designed 
without  the  combination  of  new drugs  that  may 
enhance  graft-versus-myeloma  effects  to  allow 
long-term disease control and prolong survival even 
in  patients  with  high  risk  disease.  Profound 
cytoreduction  before  and  enhanced  graft-versus-
myeloma  effects  after  allografts  through  the 
immunomodulatory properties of lenalidomide and Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
bortezomib may be key factors to improve clinical 
outcomes.  
Optimal timing  of  an  allograft  and  dosage  of 
new drugs remain to be determined and should be 
explored  prospectively  only  in  the  context  of 
clinical trials and not routinely recommended. 
References:
1. Gahrton G, Tura S, Ljungman P, et al.   Allogeneic bone 
marrow transplantation in multiple myeloma.  N Engl J Med 
1991;325:1267-1273.
2. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic 
marrow transplantation for multiple myeloma: An analysis 
of risk factors on outcome. Blood 1996;88:2787-2793.
3. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in 
allogeneic  bone  marrow  transplantation  for  multiple 
myeloma. J Clin Oncol 1995;13:1312-1322.
4. Barlogie  B,  Kyle  RA,  Anderson  KC,  et  al.  Standard 
chemotherapy compared with high-dose chemoradiotherapy 
for  multiple  myeloma:  final  results  of  phase  III  US 
Intergroup Trial S9321. J Clin Oncol 2006;24(6): 929-936. 
5. Bensinger  WI,  Maloney  D,  Storb  R.  Allogeneic 
hematopoietic  cell  transplantation  for  multiple  myeloma. 
Semin Hemalol 2001;38: 243-249. 
6. Reece DE, Shepherd JD, Klingemann HG, et al. Treatment 
of  myeloma  using  intensive  therapy  and  allogeneic  bone 
marrow transplantation. Bone Marrow Transplant 1995;15: 
117-123.
7. Alyea  E,  Weller  E,  Schlossman  R,  et  al.  T-cell-depleted 
allogeneic bone marrow transplantation followed by donor 
lymphocyte  infusion  in  patients  with  multiple  myeloma: 
induction  of  graft-versus-myeloma  effect.  Blood  2001;98: 
934-939.
8. Kulkarni  S,  Powles  RL,  Treleaven  JG,  et  al.  Impact  of 
previous high-dose therapy on outcome after allografting for 
multiple myeloma. Bone Marrow Transplant 1999;23: 675-
680.
9. Le  Blanc  R,  Montminy-Métivier  S,  Bélanger  R,  et  al. 
Allogeneic  transplantation  for  multiple  myeloma:  further 
evidence  for  a  GVHD-associated  graft-versus-myeloma 
effect. Bone Marrow Transplant 2001;28: 841-848.
10. Couban  S,  Stewart  AK,  Loach  D,  et  al.  Autologous  and 
allogeneic transplantation for multiple myeloma at a single 
centre. Bone Marrow Transplant 1997;19:783-789. 
11. Varterasian  M,  Janakiraman  N,  Karanes  C,  et  al. 
Transplantation  in  patients  with  multiple  myeloma:  a 
multicenter comparative analysis of peripheral blood stem 
cell and  allogeneic transplant. Am J  Clin  Oncol 1997;20: 
462-466.
12. Russell  NH,  Miflin  G,  Stainer  C,  et  al.  Allogeneic  bone 
marrow  transplant  for  multiple  myeloma.  Blood  1997;89: 
2610-2611. (Letter)
13. Cavo M, Bandini G, Benni M, et al. High-dose busulfan and 
cyclophosphamide are an effective conditioning regimen for 
allogeneic  bone  marrow  transplantation  in  chemosensitive 
multiple myeloma. Bone Marrow Transplant 1998;22:27-32.
14. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic 
bone marrow and peripheral blood stem cell transplantation 
for  multiple  myeloma:  a  comparison  between  transplants 
performed  1983-93  and  1994-8  at  European  Group  for 
Blood and Marrow Transplantation centres. Br J Haematol 
2001;113:209-216.
15. McSweeney  PA,  Niederwieser  D,  Shizuru  JA,  et  al. 
Hematopoietic  cell  transplantation  in  older  patients  with 
hematologic  malignancies:  replacing  high-dose  cytotoxic 
therapy  with  graft-versus-tumor  effects.  Blood 
2001;97:3390-3400.
16. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with 
nonmyeloablative  conditioning  following  cytoreductive 
autografts  for  the  treatment  of  patients  with  multiple 
myeloma. Blood 2003;102:3447-3454.
17. Kröger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem 
cell  transplantation  followed  by  a  dose-reduced  allograft 
induces high complete remission rate in multiple myeloma. 
Blood 2002;100:755-760.
18. Rotta M, Storer BE, Sahebi F, et al. Long-term outcome of 
patients  with  multiple  myeloma  after  autologous 
hematopoietic  cell  transplantation  and  nonmyeloablative 
allografting. Blood. 2009;113:3383-91.
19. Bruno  B,  Rotta  M,  Patriarca  F,  et  al.  Non-myeloablative 
allografting  for  newly  diagnosed  multiple  myeloma:  the 
experience  of  the  Gruppo  Italiano  Trapianti  di  Midollo. 
Blood. 2008;113:3375-82.
20. Mohty  M,  Boiron  JM,  Damaj  G,  et  al.  Graft-versus-
myeloma  effect  following  antithymocyte  globulin-based 
reduced  intensity  conditioning  allogeneic  stem  cell 
transplantation. Bone Marrow Transplant 2004;34:77-84.
21. Peggs  KS,  Mackinnon  S,  Williams  CD,  et  al.  Reduced-
intensity transplantation with  in vivo  T-cell depletion  and 
adjuvant  dose-escalating  donor  lymphocyte  infusions  for 
chemotherapy-sensitive myeloma: Limited efficacy of graft-
versus-tumor  activity.  Biol Blood  Marrow  Transplant 
2003;9: 257-265.
22. Einsele H, Schäfer HJ, Hebart H, et al. Follow-up of patients 
with  progressive  multiple  myeloma  undergoing  allografts 
after  reduced-intensity  conditioning.  Br  J  Haematol 
2003;121: 411-418.
23. Giralt  S,  Aleman  A,  Anagnostopoulos  A,  et  al. 
Fludarabine/melphalan  conditioning  for  allogeneic 
transplantation  in  patients  with  multiple  myeloma.  Bone 
Marrow Transplant 2002;30:367-373.
24. Gerull S, Goerner M, Benner A, et al. Long-term outcome of 
nonmyeloablative allogeneic transplantation in patients with 
high-risk  multiple  myeloma.  Bone  Marrow  Transplant 
2005;36:963-969.
25. Bruno  B,  Sorasio  R,  Patriarca  F,  et  al.  Unrelated  donor 
haematopoietic cell transplantation after non-myeloablative 
conditioning for patients with high-risk multiple myeloma. 
Eur J Haematol 2007;78:330-337.
26. Lee CK, Badros A, Barlogie B, et al. Prognostic factors in 
allogeneic  transplantation  for  patients  with  high-risk 
multiple myeloma after reduced intensity conditioning. Exp 
Hematol 2003;31:73-80.
27. Kröger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem 
cell  transplantation  in  multiple  myeloma  after  a  reduced-
intensity conditioning with pretransplantation antithymocyte 
globulin is highly effective with low transplantation-related 
mortality. Blood 2002;100:3919-3924.
28. Crawley  C,  Iacobelli  S,  Björkstrand  B,  et  al.  Reduced-
intensity  conditioning  for  myeloma:  lower  nonrelapse 
mortality  but  higher  relapse  rates  compared  with 
myeloablative conditioning. Blood 2007;109:3588-3594. 
29. Crawley  C,  Lalancette M, Szydlo  R,  et  al: Outcomes  for 
reduced-intensity  allogeneic  transplantation  for  multiple 
myeloma: an analysis of prognostic factors from the Chronic 
Leukaemia  Working  Party  of  the  EBMT.  Blood  2005; 
105:4532-39.
30. Wheatley  K,  Gray  R.  Commentary:  Mendelian 
randomization--an update on its use to evaluate allogeneic 
stem  cell  transplantation  in  leukaemia.  Int  J  Epidemiol 
2004;33:15-7.
31. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy 
versus  allogeneic  transplantation  for  very-high-risk 
childhood acute lymphoblastic leukaemia in first complete Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
remission:  comparison  by  genetic  randomisation  in  an 
international prospective study. Lancet  2005;366:635-42.
32. Woods  WG,  Neudorf  S,  Gold  S,  et  al.  A  comparison  of 
allogeneic  bone  marrow  transplantation,  autologous  bone 
marrow  transplantation,  and  aggressive  chemotherapy  in 
children with acute myeloid leukemia in remission. Blood 
2001;97:56-62.
33. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared 
with autologous stem cell transplantation in the treatment of 
patients younger than 46 years with acute myeloid leukemia 
(AML) in first complete remission (CR1): an intention-to-
treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 
2003;102:1232-40.
34. Garban  F,  Attal  M,  Michallet  M,  et  al.  Prospective 
comparison of autologous stem cell transplantation followed 
by  dose-reduced  allograft  (IFM99-03  trial)  with  tandem 
autologous  stem  cell  transplantation  (IFM99-04  trial)  in 
high-risk de novo multiple myeloma. Blood 2006;107:3474-
3480.
35. Moreau P, Garban F, Attal M, et al. Long-term follow-up 
results  of  IFM99-03  and  IFM99-04  trials  comparing 
nonmyeloablative  allotransplantation  with  autologous 
transplantation  in  high-risk  de  novo  multiple  myeloma. 
Blood 2008;112:3914-5. 
36. Bruno  B,  Rotta  M,  Patriarca  F,  et  al.  A  comparison  of 
allografting  with  autografting  for  newly-diagnosed 
myeloma. N Engl J Med 2007;356:1110-1120.
37. Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective 
PETHEMA  study  of  tandem  autologous  transplantation 
versus autograft followed by reduced-intensity conditioning 
allogeneic  transplantation  in  newly  diagnosed  multiple 
myeloma. Blood. 2008;112:3591-3. 
38. Lokhorst  H,  Sonneveld  P,  van  der  Holt  B,  et  al:  Donor 
Versus No Donor Analysis of Newly Diagnosed Myeloma 
Patients Included in the HOVON 50/54 Study. Blood (ASH 
Annual Meeting Abstracts) 2008; 112: 461. 
39. Gahrton  G,  Bjorkstrand  B,  Iacobelli  S,  et  al:  Tandem 
Autologous(ASCT)/Allogeneic  Reduced  Intensity 
Conditioning  Transplantation  (RIC)  with  Identical  Sibling 
Donor  Versus  ASCT  in  Previously  Untreated  Multiple 
Myeloma  (MM):  Long  Term  Follow  up  of  a  Prospective 
Controlled  Trial  by  the  EBMT.  Blood  (ASH  Annual 
Meeting Abstracts) 2009; 114:52. 
40. Knop S, Liebisch P, Hebart H, et al: Allogeneic Stem Cell 
Transplant versus Tandem High-Dose Melphalan for Front-
Line Treatment of Deletion 13q14 Myeloma – An Interim 
Analysis  of  the  German  DSMM  V  Trial.  Blood  (ASH 
Annual Meeting Abstracts) 2009; 114:51. 
41. Verdonck  LF,  Lokhorst  HM,  Dekker  AW,  et  al.  Graft-
versus-myeloma effect in two cases. Lancet 1996;347:800-
801. 
42. Aschan  J,  Lönnqvist  B,  Ringdén  O,  et  al. Graft-versus-
myeloma effect. Lancet 1996;348:346. (Letter)
43. Libura  J,  Hoffmann  T,  Passweg  J,  et  al.  Graft-versus-
myeloma after withdrawal of immunosuppression following 
allogeneic  peripheral  stem  cell  transplantation.  Bone 
Marrow Transplant 1999;24:925-927.
44. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor 
leukocyte  infusions  are  effective  in  relapsed  multiple 
myeloma  after  allogeneic  bone  marrow  transplantation. 
Blood 1997;90: 4206-4211. 
45. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor 
lymphocyte infusions for relapsed multiple myeloma after 
allogeneic  stem-cell  transplantation:  predictive  factors  for 
response  and  long-term  outcome.  J  Clin  Oncol  2000;18: 
3031-3037. 
46. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of 
graft-versus-host disease is the major predictive factor for 
response  to  donor  lymphocyte  infusions  in  multiple 
myeloma. Blood 2004;103: 4362–4364. 
47. Van de Donk NW, Kröger N, Hegenbart U, et al. Prognostic 
factors  for  donor  lymphocyte  infusions  following  non-
myeloablative  allogeneic  stem  cell  transplantation  in 
multiple myeloma. Bone Marrow Transplant 2006;37:1135-
1141.
48. Corradini  P,  Voena  C,  Tarella  C,  et  al.  Molecular  and 
clinical remissions in multiple myeloma: role of autologous 
and allogeneic transplantation of hematopoietic cells. J Clin 
Oncol 1999;17:208-215.
49. Richardson  PG,  Sonneveld  P,  Schuster  MW,  et  al. 
Bortezomib  or  high-dose  dexamethasone  for  relapsed 
multiple myeloma. N Engl J Med. 2005;352:2487-2498.
50. Dimopoulos  M,  Spencer A,  Attal M,  et  al.  Lenalidomide 
plus  dexamethasone  for  relapsed  or  refractory  multiple 
myeloma. N Engl J Med. 2007;357:2123-2132.
51. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus 
dexamethasone  for  relapsed  multiple  myeloma  in  North 
America. N Engl J Med. 2007;357:2133-2142.
52. Palumbo A, Bringhen S, Caravita T, et al.: Italian Multiple 
Myeloma  Network,  GIMEMA.  Oral  melphalan  and 
prednisone chemotherapy plus thalidomide compared  with 
melphalan  and  prednisone  alone  in  elderly  patients  with 
multiple  myeloma:  randomised  controlled  trial.  Lancet. 
2006;367:825-31.
53. Kröger  N,  Shimoni  A,  Zagrivnaja  M,  et  al:  Low-dose 
thalidomide  and  donor  lymphocyte  infusion  as  adoptive 
immunotherapy after allogeneic stem cell transplantation in 
patients  with  multiple  myeloma.  Blood  2004;104:3361-
3363. 
54. Minnema  MC,  van  der  Veer  MS,  Aarts  T,  et  al: 
Lenalidomide alone or in combination with dexamethasone 
is  highly  effective  in  patients  with  relapsed  multiple 
myeloma following allogeneic stem cell transplantation and 
increases the frequency of CD4+Foxp3+ T cells. Leukemia 
2009; 23:605-607. 
55. Lioznov M, El-Cheikh J Jr, Hoffmann F, et al: Lenalidomide 
as salvage therapy after allo-SCT for multiple myeloma is 
effective  and  leads  to  an  increase  of  activated  NK 
(NKp44(+))  and  T  (HLA-DR(+))  cells.  Bone  Marrow 
Transplant 2010; 45:349-353
56. Minnema  MC,  van  der  Holt  B,  Kersten  MJ,  et  al:  First 
Interim Analysis of HOVON 76: Lenalidomide Maintenance 
Following  Non  Myeloablative  Allogeneic  Stem  Cell 
Transplantation in Patients with Multiple Myeloma. Blood 
(ASH Annual Meeting Abstracts) 2009; 114: 2285.
57. Kröger N, Zabelina T, Ayuk F, et al: Bortezomib after dose-
reduced  allogeneic  stem  cell  transplantation  for  multiple 
myeloma  to  enhance  or  maintain  remission  status.  Exp 
Hematol. 2006; 34:770-775.
58. van  de  Donk  NW,  Kroger  N,  Hegenbart  U,  et  al: 
Remarkable  activity  of  novel  agents  bortezomib  and 
thalidomide in patients not responding to donor lymphocyte 
infusions  following  nonmyeloablative allogeneic stem cell 
transplantation  in  multiple  myeloma.  Blood 2006;  107: 
3415-3416.
59. Kröger N,  Badbaran  A,  Lioznov  M, et  al: Post-transplant 
immunotherapy with donor-lymphocyte infusion and novel 
agents  to  upgrade  partial  into  complete  and  molecular 
remission  in  allografted  patients  with  multiple  myeloma. 
Exp Hematol. 2009; 37:791-798.
60. Bruno B, Patriarca F, Sorasio R, et al. Bortezomib with or 
without  dexamethasone  in  relapsed  multiple  myeloma 
following  allogeneic  hematopoietic  cell  transplantation. 
Haematologica. 2006;91:837-9. 
61. Sun  K,  Welniak  LA,  Panoskaltsis-Mortari  A.,  et  al: 
Inhibition of acute graft-versus-host disease with retention 
of  graft-versus-tumor  effects  by  the  proteasome  inhibitor 
bortezomib.  Proc.Natl.Acad.Sci.U.S.A  2004;  101:8120-
8125.
62. Sun K, Wilkins DE, Anver MR, Sayers TJ, et al: Differential 
effects of proteasome inhibition by bortezomib on murine 
acute  graft-versus-host  disease  (GVHD):  delayed 
administration  of  bortezomib  results  in  increased  GVHD-
dependent gastrointestinal toxicity. Blood 2005; 106:3293-
3299.
63. Blanco  B,  Pérez-Simón  JA,  Sánchez-Abarca  LI,  et  al: 
Bortezomib  induces  selective  depletion  of  alloreactive  T 
lymphocytes and decreases the production of Th1 cytokines. 
Blood 2006; 107: 3575-3583.Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
64. Blanco  B,  Pérez-Simón  JA,  Sánchez-Abarca  LI,  et  al: 
Treatment  with  bortezomib  of  human  CD4+  T  cells 
preserves  natural  regulatory  T  cells  and  allows  the 
emergence  of  a  distinct  suppressor  T-cell  population. 
Haematologica 2009; 94:975-983.
65. Koreth  J,  Stevenson  KE,  Kim  HT,  et  al:  Bortezomib, 
tacrolimus,  and  methotrexate  for  prophylaxis  of  graft-
versus-host  disease  after  reducedintensity  conditioning 
allogeneic stem cell transplantation from HLAmismatched 
unrelated donors. Blood 2009; 114: 3956–3959.
66. Kroger N, Perez-Simon JA, Myint H, et al: Relapse to prior 
autograft  and  chronic  graft-versus-host  disease  are  the 
strongest  prognostic  factors  for  outcome  of 
melphalan/fludarabine-based  dose-reduced  allogeneic  stem 
cell transplantation in patients with multiple myeloma. Biol 
Blood Marrow Transplant 2004; 10: 698-708.
67. Lee CK, Badros A, Barlogie B, et al: Prognostic factors in 
allogeneic  transplantation  for  patients  with  high-risk 
multiple myeloma after reduced intensity conditioning. Exp 
Hematol 2003; 31: 73-80..
68. Siegel S, Wagner A, Friedrichs B, et al.: Identification of 
HLA-A*0201-presented  T  cell  epitopes  derived  from  the 
oncofetal  antigen-immature  laminin  receptor  protein  in 
patients with hematological malignancies. J Immunol 2006; 
76: 6935-6944. 